Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.

Abstract

Background:

Muscle-invasive bladder cancer (MIBC) and upper urinary tract urothelial carcinoma (UTUC) are molecularly heterogeneous. Despite chemotherapies, immunotherapies, or anti-fibroblast growth factor receptor (FGFR) treatments, these tumors are still of a poor outcome. Our objective was to develop a bank of patient-derived xenografts (PDXs) recapitulating the molecular heterogeneity of MIBC and UTUC, to facilitate the preclinical identification of therapies.

Methods:

Fresh tumors were obtained from patients and subcutaneously engrafted into immune-compromised mice. Patient tumors and matched PDXs were compared regarding histopathology, transcriptomic (microarrays), and genomic profiles [targeted Next-Generation Sequencing (NGS)]. Several PDXs were treated with chemotherapy (cisplatin/gemcitabine) or targeted therapies [FGFR and epidermal growth factor (EGFR) inhibitors].

Results:

A total of 31 PDXs were established from 1 non-MIBC, 25 MIBC, and 5 upper urinary tract tumors, including 28 urothelial (UC) and 3 squamous cell carcinomas (SCCs). Integrated genomic and transcriptomic profiling identified the PDXs of three different consensus molecular subtypes [basal/squamous (Ba/Sq), luminal papillary, and luminal unstable] and included FGFR3-mutated PDXs. High histological and genomic concordance was found between matched patient tumor/PDX. Discordance in molecular subtypes, such as a Ba/Sq patient tumor giving rise to a luminal papillary PDX, was observed (n=5) at molecular and histological levels. Ten models were treated with cisplatin-based chemotherapy, and we did not observe any association between subtypes and the response. Of the three Ba/Sq models treated with anti-EGFR therapy, two models were sensitive, and one model, of the sarcomatoid variant, was resistant. The treatment of three FGFR3-mutant PDXs with combined FGFR/EGFR inhibitors was more efficient than anti-FGFR3 treatment alone.

Conclusions:

We developed preclinical PDX models that recapitulate the molecular heterogeneity of MIBCs and UTUC, including actionable mutations, which will represent an essential tool in therapy development. The pharmacological characterization of the PDXs suggested that the upper urinary tract and MIBCs, not only UC but also SCC, with similar molecular characteristics could benefit from the same treatments including anti-FGFR for FGFR3-mutated tumors and anti-EGFR for basal ones and showed a benefit for combined FGFR/EGFR inhibition in FGFR3-mutant PDXs, compared to FGFR inhibition alone.

• Authors: Hervé Lang, Claire Béraud, Luc Cabel, Jacqueline Fontugne, Myriam Lassalle, Clémentine Krucker, Florent Dufour, Clarice S Groeneveld, Victoria Dixon, Xiangyu Meng, Aurélie Kamoun, Elodie Chapeaublanc, Aurélien De Reynies, Xavier Gamé, Pascal Rischmann, Ivan Bieche, Julien Masliah-Planchon, Romane Beaurepere, Yves Allory, Véronique Lindner, Yolande Misseri, François Radvanyi, Philippe Lluel, Isabelle Bernard-Pierrot, Thierry Massfelder
• Journal: Frontiers in oncology (Front Oncol) Vol. 12 Pg. 930731 ( 2022) ISSN: 2234-943X [Print] Switzerland
• PMID: 36033544 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Lang, Béraud, Cabel, Fontugne, Lassalle, Krucker, Dufour, Groeneveld, Dixon, Meng, Kamoun, Chapeaublanc, De Reynies, Gamé, Rischmann, Bieche, Masliah-Planchon, Beaurepere, Allory, Lindner, Misseri, Radvanyi, Lluel, Bernard-Pierrot and Massfelder.